ABCSG 40 Trial Summary

A phase II, randomized, double-blind placebo controlled, study of letrozole with or without BYL719, for the neoadjuvant treatment of postmenopausal women with hormonereceptor-positive HER2-negative breast cancer

Start: 09/2013; national: 07/2014
Coordinating Investigator: Egle, Daniel; Innsbruck
Sample size: 320 (international), 40 (national)
Design:
(Click to enlarge)
Design ABCSG-40

Link for studyteam-members only

Further information about this trial

Access to these informations only with keyword. If required, please ask the responsible project manager.